Insider Transactions in Q4 2021 at Kymera Therapeutics, Inc. (KYMR)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 16
2021
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+1.67%
|
$16,000
$2.08 P/Share
|
|
Dec 03
2021
|
Bruce N. Jacobs Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-13.25%
|
$540,000
$54.23 P/Share
|
|
Dec 03
2021
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+26.66%
|
$20,000
$2.08 P/Share
|
|
Nov 23
2021
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+36.69%
|
$20,000
$2.08 P/Share
|
|
Nov 02
2021
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
14,996
-14.36%
|
$944,748
$63.58 P/Share
|
|
Nov 02
2021
|
Jared Gollob Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,996
+27.44%
|
$29,992
$2.08 P/Share
|
|
Nov 01
2021
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
42,497
-21.53%
|
$2,592,317
$61.85 P/Share
|
|
Nov 01
2021
|
Jared Gollob Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,607
+15.32%
|
$24,607
$1.7 P/Share
|
|
Oct 11
2021
|
Nello Mainolfi Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
6,456
-0.69%
|
$348,624
$54.04 P/Share
|
|
Oct 11
2021
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,456
+1.35%
|
$12,912
$2.08 P/Share
|
|
Oct 08
2021
|
Nello Mainolfi Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
41,544
-1.41%
|
$2,409,552
$58.52 P/Share
|
|
Oct 08
2021
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
41,544
+7.59%
|
$83,088
$2.08 P/Share
|